

# Updated ARROW data: pralsetinib in patients with advanced or metastatic *RET*-altered thyroid cancer

Mimi I Hu<sup>1</sup>, Vivek Subbiah<sup>2</sup>, Aaron S Mansfield<sup>3</sup>, Matthew H Taylor<sup>4</sup>, Martin Schuler<sup>5</sup>, Viola W Zhu<sup>6</sup>, Julien Hadoux<sup>7</sup>, Giuseppe Curigliano<sup>8</sup>, Lori J Wirth<sup>9</sup>, Elena Garralda<sup>10</sup>, Douglas Adkins<sup>11</sup>, Yann Godbert<sup>12</sup>, Myung-Ju Ahn<sup>13</sup>, Philippe Cassier<sup>14</sup>, Byoung Chul Cho<sup>15</sup>, Chia-Chi Lin<sup>16</sup>, Teresa Barata<sup>17</sup>, Alena Zalutskaya<sup>18</sup>, Astrid Scalori<sup>19</sup>, Marcia S Brose<sup>20</sup>

## BACKGROUND

- Oncogenic *RET* alterations are targetable biomarkers in thyroid cancer.<sup>1</sup>
- Multikinase inhibitors (MKI) are therapeutic options in medullary thyroid cancer (MTC); cabozantinib and vandetanib) and differentiated thyroid cancer (cabozantinib, lenvatinib and sorafenib); however, MKI-related adverse events leading to dose reductions and drug discontinuation are frequent.<sup>2-4</sup>
- Pralsetinib is a potent, selective *RET* kinase inhibitor**<sup>1</sup> that has shown clinical activity in patients with *RET*-altered thyroid cancer in the phase 1/2 ARROW trial (NCT03037385; data cut-off: 12 Apr 2021; intention-to-treat [ITT] population).<sup>5,6</sup>
  - Overall response rate (ORR) by blinded independent central review (BICR) was 51% in patients with *RET*-mutant MTC previously treated with cabozantinib and/or vandetanib (C/V), 72% in treatment-naïve patients with *RET*-mutant MTC, and 86% in patients with previously treated *RET* fusion-positive thyroid cancer (*RET*-fp TC).
- We present updated data for these three cohorts (**data cut-off: 18 Oct 2021**).

## METHODS

- Adult patients with *RET*-altered locally advanced/metastatic thyroid cancer who had enrolled in ARROW and initiated oral pralsetinib at 400 mg QD prior to the enrolment cut-off (**18 Feb 2021**) were included in the **ITT population**
  - The *RET*-altered **measurable disease population** included patients from the ITT population who had measurable disease at baseline (by BICR per RECIST v1.1).
- The *RET*-altered thyroid cancer **safety population** comprised all patients who had received ≥1 dose of pralsetinib 400 mg QD prior to the data cut-off.
- Phase 2 primary endpoints:** **ORR by BICR** per RECIST v1.1, and safety.
- Key secondary endpoints: duration of response (DoR), progression-free survival (PFS) and overall survival (OS).
- ORR and DoR were evaluated in both the measurable disease and the ITT populations; PFS and OS were only assessed in the ITT population.

### Affiliations

<sup>1</sup>Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Email: [mhu@mdanderson.org](mailto:mhu@mdanderson.org); <sup>2</sup>Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA; <sup>3</sup>Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA; <sup>4</sup>Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon, USA; <sup>5</sup>West German Cancer Center, University Hospital Essen, Essen, Germany; <sup>6</sup>Department of Medicine, University of California Irvine, Orange, California, USA; <sup>7</sup>Department of Endocrine Oncology, Gustave Roussy, Villejuif, France; <sup>8</sup>European Institute of Oncology, IRCCS, and University of Milano, Milan, Italy; <sup>9</sup>Center for Head and Neck Cancers, Massachusetts General Hospital, Boston, Massachusetts, USA; <sup>10</sup>Vall d'Hebron Institute of Oncology, Hospital Universitario Vall d'Hebron, Barcelona, Spain; <sup>11</sup>Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, Missouri, USA; <sup>12</sup>Nuclear Medicine and Thyroid Oncology Department, Bergonié Institute Cancer Center, Bordeaux, France; <sup>13</sup>Department of Hematology & Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; <sup>14</sup>Department of Medical Oncology, Centre Léon Bérard, Lyon, France; <sup>15</sup>Yonsei University College of Medicine, Yonsei Cancer Center, Seoul, Republic of Korea; <sup>16</sup>Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan; <sup>17</sup>Biostatistics, F. Hoffmann-La Roche Ltd, Basel, Switzerland; <sup>18</sup>Clinical Development Oncology, Blueprint Medicines Corporation, Cambridge, Massachusetts, USA; <sup>19</sup>Global Product Development Oncology, F. Hoffmann-La Roche Ltd, Welwyn Garden City, United Kingdom; <sup>20</sup>Department of Medical Oncology, Sydney Kimmel Cancer Center, Jefferson University, Philadelphia, Pennsylvania, USA

## RESULTS

### Patient population

- At data cut-off, the ITT population included 145 patients with *RET*-mutant MTC (prior C/V: n=67; other prior systemic therapy: n=11; treatment naïve: n=67) and 25 patients with *RET*-fp TC who had received prior systemic therapy, including radioactive iodine (**Table 1**).

**Table 1. Patient demographics and baseline characteristics (ITT population)**

	<i>RET</i> -mutant MTC: prior C/V (n=67)	<i>RET</i> -mutant MTC: treatment naïve (n=67)	<i>RET</i> -fp TC: prior systemic treatment (n=25)
<b>Median age, years (range)</b>	<b>59 (25–83)</b>	<b>55 (18–81)</b>	<b>60 (23–74)</b>
<b>Female, n (%)</b>	<b>23 (34.3)</b>	<b>24 (35.8)</b>	<b>16 (64.0)</b>
<b>Race, n (%)</b>			
White / Asian	55 (82.1) / 3 (4.5)	27 (40.3) / 37 (55.2)	16 (64.0) / 8 (32.0)
Other or not reported	9 (13.4)	3 (4.5)	1 (4.0)
<b>ECOG PS, n (%)</b>			
0	18 (26.9)	38 (56.7)	11 (44.0)
1	46 (68.7)	29 (43.3)	14 (56.0)
2*	3 (4.5)	0	0
<b>Prior systemic therapy in any setting, n (%)</b>			
Chemotherapy / immunotherapy C/V / L/S	7 (10.4) / 3 (4.5)	No prior antineoplastic treatment	1 (4.0) / 0
Radioactive iodine	67 (100.0) / 5 (7.5)		3 (12.0) / 14 (56.0)
<b>No. of prior lines of systemic therapy, n (%)</b>			
1 / 2	31 (46.3) / 24 (35.8)	No prior antineoplastic treatment	10 (40.0) / 5 (20.0)
≥3	12 (17.9)		10 (40.0)
<b>Baseline CNS metastases, n (%)</b>	<b>7 (10.4)</b>	<b>6 (9.0)</b>	<b>10 (40.0)</b>

\*ECOG performance status of 2 was permitted before a protocol amendment. C/V, cabozantinib and/or vandetanib; CNS, central nervous system; ECOG PS, Eastern Cooperative Oncology Group performance status; ITT, intention-to-treat; L/S, lenvatinib and/or sorafenib; MTC, medullary thyroid cancer; *RET*-fp TC, *RET* fusion-positive thyroid cancer.

**Table 2. Overall efficacy**

	Measurable disease population			ITT population		
	<i>RET</i> -mutant MTC: prior C/V (n=61)	<i>RET</i> -mutant MTC: treatment naïve (n=62)	<i>RET</i> -fp TC: prior systemic treatment (n=22)	<i>RET</i> -mutant MTC: prior C/V (n=67)	<i>RET</i> -mutant MTC: treatment naïve (n=67)	<i>RET</i> -fp TC: prior systemic treatment (n=25)
<b>ORR*, n (%) [95% CI]</b>	<b>34 (55.7) [42.4–68.5]</b>	<b>48 (77.4) [65.0–87.1]</b>	<b>20 (90.9) [70.8–98.9]</b>	<b>35 (52.2) [39.7–64.6]</b>	<b>48 (71.6) [59.3–82.0]</b>	<b>21 (84.0) [63.9–95.5]</b>
CR	1 (1.6)	4 (6.5)	3 (13.6)	2 (3.0)	4 (6.0)	4 (16.0)
PR	33 (54.1)	44 (71.0)	17 (77.3)	33 (49.3)	44 (65.7)	17 (68.0)
SD	23 (37.7)	11 (17.7)	2 (9.1)	27 (40.3)	13 (19.4)	4 (16.0)
PD	2 (3.3)	2 (3.2)	0	2 (3.0)	2 (3.0)	0
Not evaluable	2 (3.3)	1 (1.6)	0	3 (4.5)	4 (6.0)	0
<b>Median DoR**†, months, [95% CI]</b>	<b>25.8 [18.0–NE]</b>	<b>NR [NE–NE]</b>	<b>23.6 [15.1–NE]</b>	<b>25.8 [18.0–NE]</b>	<b>NR [NE–NE]</b>	<b>23.6 [15.1–NE]</b>
Events, n (%)	18 (52.9)	8 (16.7)	8 (40.0)	18 (51.4)	8 (16.7)	8 (38.1)
18-month rate, % [95% CI]	<b>67.5 [50.9–84.1]</b>	<b>79.8 [65.9–93.7]</b>	<b>50.2 [22.0–78.3]</b>	<b>68.5 [52.3–84.7]</b>	<b>79.8 [65.9–93.7]</b>	<b>53.9 [27.3–80.6]</b>

\*Assessed by central radiology review per RECIST v1.1. †DoR analysis includes patients with confirmed CR/PR; DoR results per EMA censoring rules. C/V, cabozantinib and/or vandetanib; CI, confidence interval; CR, complete response; DoR, duration of response; EMA, European Medicines Agency; ITT, intention-to-treat; MTC, medullary thyroid cancer; NE, not estimable; NR, not reached; ORR, overall response rate; PD, progressive disease; PR, partial response; RECIST, Response Evaluation Criteria In Solid Tumors; *RET*-fp TC, *RET* fusion-positive thyroid cancer; SD, stable disease.


### Overall efficacy

- In the ITT population ORR was (**Table 2**):
  - 52.2%** (95% CI: 39.7–64.6) in patients with *RET*-mutant MTC who had received prior C/V
  - 71.6%** (95% CI: 59.3–82.0) in treatment-naïve patients with *RET*-mutant MTC
  - 84.0%** (95% CI: 63.9–95.5) in patients with previously treated *RET*-fp TC.
- Similar results were observed in the measurable disease population (**Table 2**).
- Responses were observed regardless of the *RET* mutation genotype (**Figure 1**).
- In the ITT population, median DoR was (**Table 2**):
  - 25.8 months** in patients with *RET*-mutant MTC who had received prior C/V
  - Not reached** in treatment-naïve patients with *RET*-mutant MTC
  - 23.6 months** in patients with previously treated *RET*-fp TC.

### Survival endpoints

- In patients with *RET*-mutant MTC, median PFS was **25.8 months** (prior C/V) and **not reached** (treatment naïve; **Table 3**; **Figure 2A**).
- Patients with previously treated *RET*-fp TC had a median PFS of **25.4 months** (**Table 3**; **Figure 2B**).
- Median OS was **not reached** in any of the three populations (**Table 3**).

**Figure 1. Best improvement from baseline in target lesion diameter in patients with *RET*-mutant MTC who A) had received prior C/V or B) were treatment naïve**



\*By central radiology assessment per RECIST v1.1. ITT population. C/V, cabozantinib and/or vandetanib; ITT, intention-to-treat; MTC, medullary thyroid cancer; RECIST, Response Evaluation Criteria In Solid Tumors; SLD, sum of longest diameters.

**Table 3. Survival endpoints (ITT population)**

	<i>RET</i> -mutant MTC: prior C/V (n=67)	<i>RET</i> -mutant MTC: treatment naïve (n=67)	<i>RET</i> -fp TC: prior systemic treatment (n=25)
<b>Median PFS*, months [95% CI]</b>	<b>25.8 [19.7–35.0]</b>	<b>NR [27.5–NE]</b>	<b>25.4 [17.0–NE]</b>
18-month rate, % [95% CI]	<b>66.9 [55.0–78.9]</b>	<b>79.4 [69.4–89.5]</b>	<b>62.3 [41.2–83.5]</b>
<b>Median OS, months [95% CI]</b>	<b>NR [36.9–NE]</b>	<b>NR [NE–NE]</b>	<b>NR [17.7–NE]</b>
18-month rate, % [95% CI]	<b>85.3 [76.3–94.2]</b>	<b>90.8 [83.7–97.8]</b>	<b>69.6 [48.9–90.4]</b>

\*Assessed by BICR per RECIST v1.1. PFS results per EMA censoring rules. BICR, blinded independent central review; C/V, cabozantinib and/or vandetanib; CI, confidence interval; EMA, European Medicines Agency; ITT, intention-to-treat; MTC, medullary thyroid cancer; NR, not reached; NE, not estimable; OS, overall survival; PFS, progression-free survival; RECIST, Response Evaluation Criteria In Solid Tumors; *RET*-fp TC, *RET* fusion-positive thyroid cancer.

### Disclosures

Mimi I. Hu reports steering committee (no financial re-imbursement) for Eli Lilly & Co; institutional research funding from Eli Lilly & Co; and has served as a co-investigator for Eli Lilly & Co and Roche studies.


### Acknowledgements

This study was conducted by Blueprint Medicines and F. Hoffmann-La Roche Ltd (study sponsor). Further statistical support was provided by Jerome Chague of F. Hoffmann-La Roche Ltd and Hui Zhang of Blueprint Medicines. Third party medical writing assistance, under the direction of the authors, was provided by Lynn Cairncross-Kashorte, MA, of Ashfield MedComms, an Inizio company, and was funded by F. Hoffmann-La Roche Ltd.

### References

- Subbiah, et al. Cancer Discov 2020
- Viola, et al. Endocr Relat Cancer 2016
- Brose, et al. Lancet Oncol 2021
- Fleeman, et al. BMC Cancer 2019
- Subbiah, et al. Lancet Diabetes Endocrinol 2021
- Mansfield, et al. J Clin Oncol 2022

**Figure 2. PFS in A) patients with *RET*-mutant MTC and B) patients with previously treated *RET*-fp TC**



C/V, cabozantinib and/or vandetanib; PFS, progression-free survival; *RET*-fp TC, *RET* fusion-positive thyroid cancer; *RET*-mut MTC, *RET*-mutant medullary thyroid cancer.

### Safety

- The *RET*-altered thyroid cancer safety population included 175 patients (**Table 4**):
  - 29 patients (16.6%) experienced serious treatment-related adverse events (TRAEs)
    - 17.9% of patients with *RET*-mutant MTC reported serious TRAEs; the most frequent was **pneumonitis** (2.8%)
    - Serious TRAEs (one event each: **anaemia**, **dizziness**, **hypotension** and **pneumonitis**) were reported in 3/30 (10.0%) of patients with *RET*-fp TC
  - One patient died due to a TRAE (*pneumocystis jirovecii* pneumonia)
  - TRAEs led to dose reduction or discontinuation in 52.6% and 5.7% of patients, respectively.

**Table 4. Safety summary for TRAEs**

Patients, n (%)	<i>RET</i> -altered thyroid cancer safety population (N=175)	
	<i>RET</i> -mutant MTC safety population (n=145)	<i>RET</i> -fp TC safety population (n=30)
<b>TRAEs</b>	<b>142 (97.9)</b>	<b>28 (93.3)</b>
<b>Serious TRAEs</b>	<b>26 (17.9)</b>	<b>3 (10.0)</b>
<b>Grade ≥3 TRAEs</b>	<b>91 (62.8)</b>	<b>16 (53.3)</b>
<b>TRAE leading to dose reduction</b>	<b>77 (53.1)</b>	<b>15 (50.0)</b>
<b>TRAE leading to dose interruption</b>	<b>87 (60.0)</b>	<b>15 (50.0)</b>
<b>TRAE leading to discontinuation</b>	<b>8 (5.5)</b>	<b>2 (6.7)</b>

Adverse events were coded using MedDRA 19.1. MTC, medullary thyroid cancer; *RET*-fp TC, *RET* fusion-positive thyroid cancer; TRAE, treatment-related adverse event.

## CONCLUSIONS

**In this updated analysis, pralsetinib continues to show efficacy and a manageable safety profile in patients with *RET*-altered thyroid cancer.**

## SUMMARY

**ORR (ITT)** **52.2%:** *RET*-mutant MTC with prior C/V  
**71.6%:** treatment-naïve *RET*-mutant MTC  
**84.0%:** previously treated *RET*-fp TC



**Consistent safety profile**



Copies of this e-poster obtained through QR, AR and/or text key codes are for personal use only and may not be reproduced without written permission of the authors.

Visit [Medically.Roche.com](https://medically.roche.com) for more information.